MARKET

AGEN

AGEN

Agenus
NASDAQ
7.56
+0.14
+1.92%
Opening 10:19 04/25 EDT
OPEN
7.35
PREV CLOSE
7.42
HIGH
7.67
LOW
7.20
VOLUME
162.46K
TURNOVER
0
52 WEEK HIGH
42.60
52 WEEK LOW
4.775
MARKET CAP
158.40M
P/E (TTM)
-0.5502
1D
5D
1M
3M
1Y
5Y
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
Agenus Inc. Is a leader in developing novel immunological agents to treat various cancers. Botensilimab in combination with balstilimAB in patients with relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases will be presented at the American Society of Clinical Oncology Meeting.
Barchart · 1d ago
Top 2 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its weakness. MultiPlan Corporation is one of the major oversold players in this sector.
Benzinga · 2d ago
AGENUS TO PROVIDE FIRST QUARTER 2024 FINANCIAL REPORT AND CORPORATE UPDATE
Reuters · 2d ago
Press Release: Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
Agenus to provide first quarter 2024 financial results before the market opens on May 7, 2024. The company will host a conference call and webcast to discuss the results and provide a corporate update. Agenus is a leader in developing novel immunological agents to treat various cancers.
Dow Jones · 2d ago
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
Agenus will release its first quarter 2024 financial results before the market opens on May 7, 2024. The company will host a conference call and webcast to discuss the results and provide a corporate update. Agenus is a leader in developing novel immunological agents to treat various cancers.
Barchart · 2d ago
Weekly Report: what happened at AGEN last week (0415-0419)?
Weekly Report · 3d ago
Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
NASDAQ · 3d ago
Weekly Report: what happened at AGEN last week (0408-0412)?
Weekly Report · 04/15 11:09
More
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.